These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 16377139)
21. Declines in NIH R01 research grant funding. Mandel HG; Vesell ES Science; 2008 Oct; 322(5899):189. PubMed ID: 18845728 [No Abstract] [Full Text] [Related]
22. Industry sponsorship and authorship of clinical trials over 20 years. Buchkowsky SS; Jewesson PJ Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982 [TBL] [Abstract][Full Text] [Related]
23. DOE to industry: so long, partner. Lawler A Science; 1996 Oct; 274(5284):24-6. PubMed ID: 8848717 [No Abstract] [Full Text] [Related]
24. Big payoffs possible for small-molecule screening. Toney JH Science; 2008 Oct; 322(5898):46. PubMed ID: 18832630 [No Abstract] [Full Text] [Related]
25. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295 [TBL] [Abstract][Full Text] [Related]
27. NIH doubles funding for San Francisco AIDS research centers. Expert Rev Anti Infect Ther; 2007 Dec; 5(6):917. PubMed ID: 18039074 [No Abstract] [Full Text] [Related]
28. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry. Dorfman HL; Reig LP Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876 [No Abstract] [Full Text] [Related]
29. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Zycher B; DiMasi JA; Milne CP Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102 [TBL] [Abstract][Full Text] [Related]
30. Ethics. Senate inquiry on research conflicts shifts to grantees. Kaiser J Science; 2008 Jun; 320(5884):1708. PubMed ID: 18583586 [No Abstract] [Full Text] [Related]
32. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Porter RJ; Baulac M; Nohria V Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575 [TBL] [Abstract][Full Text] [Related]
33. NCI restores funding to gene therapist seen as 'too hasty'. Gershon D Nature; 1994 Jun; 369(6482):598. PubMed ID: 8208279 [No Abstract] [Full Text] [Related]
34. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees. Carpenter D Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281 [TBL] [Abstract][Full Text] [Related]
35. Minimizing bias in industry-sponsored outcomes research. Freeman RA Med Interface; 1994 Apr; 7(4):130-4. PubMed ID: 10133357 [TBL] [Abstract][Full Text] [Related]
36. Stats and facts. Increasing U.S. health research expenditures. Manag Care Interface; 2001 Oct; 14(10):34-5. PubMed ID: 11688091 [No Abstract] [Full Text] [Related]
37. Advances in the clinical development of antiepileptic drugs. Porter RJ; Hessie BJ; Cereghino JJ; Gladding GD; Kupferberg HJ; Scoville B; White BG Fed Proc; 1985 Jul; 44(10):2645-9. PubMed ID: 3891417 [TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical company-sponsored drug trials: what are we to believe? Shekelle P J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207 [No Abstract] [Full Text] [Related]
39. Association between the burden of disease and research funding by the Medical Research Council of Canada and the National Institutes of Health. A cross-sectional study. Lamarre-Cliche M; Castilloux AM; LeLorier J Clin Invest Med; 2001 Apr; 24(2):83-9. PubMed ID: 11368150 [TBL] [Abstract][Full Text] [Related]
40. NIH encourages translational collaboration with industry. Wadman M Nat Rev Drug Discov; 2010 Apr; 9(4):255-6. PubMed ID: 20224566 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]